Product Images Levetiracetam Extended-release

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Levetiracetam Extended-release NDC 50228-189 by Sciegen Pharmaceuticals, Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

LEVETIRACETAM 500MG ER TABS.jpg - levetiracetam 500mg 30tabs

LEVETIRACETAM 500MG ER TABS.jpg - levetiracetam 500mg 30tabs

Each tablet contains 50 mg of Levetiracetam, USP. Follow the prescription information for usual dosage. Store at controlled room temperature and keep in a tightly closed light-resistant container out of reach of children. A medication guide must be dispensed to each patient. The tablets are extended-release and are meant for once-daily dosing. These are manufactured by StieGen Phamaceuticals, Inc. in Hauppauge, NY 11788.*

LEVETIRACETAM 500MG ER TABS.jpg - levetiracetam 500mg 500tabs

LEVETIRACETAM 500MG ER TABS.jpg - levetiracetam 500mg 500tabs

This is a medication called Levitiracetam in extended-release tablets, each containing 500mg of the active ingredient. The recommended dosage information is not provided and the user is directed to refer to the prescribing information. The medication should be stored within a specific temperature range and properly labeled as per USP controlled room temperature. The package contains 500 tablets and should be dispensed in a light-resistant container with a child-resistant closure. The manufacturer is ScieGen Pharmaceuticals, Inc based in Hauppauge, NY.*

levetiracetam 500mg 60tabs

levetiracetam 500mg 60tabs

This is a description of a medication called Levetiracetam in the form of extended-release tablets. Each tablet contains 500 mg of the medication. The prescribed dosage and further information are to be included in the accompanying prescribing information. The medication must be stored in a container with a child-resistant closure, kept away from the reach of children, and within a controlled room temperature. It is manufactured by ScieGen Pharmaceuticals, located in Hauppauge, NY. The medication guide must be dispensed to each patient by the pharmacist. The text also includes the product's NDC (National Drug Code) number, which is 50228-189-60, and its revision date, which is 12/20.*

LEVETIRACETAM 750 MG ER TABS.jpg - levetiracetam 750mg 30tabs

LEVETIRACETAM 750 MG ER TABS.jpg - levetiracetam 750mg 30tabs

This is a medication called Levetiracetam, which is available in extended-release tablets. Each coated tablet contains 750 mg of Levetiracetam, USP. The recommended storage temperature is between 20°C to 25°C (68° 0 77°F), with excursions permitted to 15° 0 30°C (59° 10 86°F), and should be kept in a tight, light-resistant container with a child-resistant closure. The medication guide should be given to each patient by a pharmacist. This medication must be kept out of reach of children. It was manufactured by ScieGen Pharmaceuticals in Hauppauge, NY 11788.*

LEVETIRACETAM 750 MG ER TABS.jpg - levetiracetam 750mg 500tabs

LEVETIRACETAM 750 MG ER TABS.jpg - levetiracetam 750mg 500tabs

This is a medication called Levetiracetam, USP which comes in the form of a 750mg easy to swallow, film-coated tablet. The usual dosage, prescription information, and storage instructions are provided. The medication should be kept out of the reach of children and prescribed with a medication guide by a pharmacist. This product is suitable for once-daily dosing and is manufactured by ScieGen Pharmaceuticals, Inc. The product comes in a tight, light-resistant container with a child-resistant closure.*

levetiracetam 750mg 60tabs

levetiracetam 750mg 60tabs

Fig1.jpg - levetiracetam fig1

Fig1.jpg - levetiracetam fig1

This appears to be a chart or table with percentages and numbers related to different dosages of levetiracetam for a study or trial, as well as a placebo group. However, without further context or information it is difficult to determine the purpose or significance of these numbers.*

Fig2.jpg - levetiracetam fig2

Fig2.jpg - levetiracetam fig2

The given text is a table of figures showing percentages and doses of three substances (not disclosed), including a placebo. The substance with a 352% figure has a statistically significant effect compared to the placebo, but the nature of the substances and their uses are not available.*

Fig3.jpg - levetiracetam fig3

Fig3.jpg - levetiracetam fig3

The study evaluated the effectiveness of immediate-release levetiracetam at 3,000mg/day compared to a placebo. The results showed that the medication was statistically significant in its effectiveness compared to the placebo group, with a reported percentage of 39.4%.*

Fig4.jpg - levetiracetam fig4

Fig4.jpg - levetiracetam fig4

The available text describes the effectiveness of immediate-release levetiracetam tablets compared to placebo. The success rate for the treatment was 44.6%, which was statistically significant compared to the 19.6% success rate for the placebo.*

levetiracetamxr-01 - levetiracetam xr 01

levetiracetamxr-01 - levetiracetam xr 01

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.